Literature DB >> 26722519

Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population.

Yipeng Ding1, Dongchuan Xu1, Xiyang Zhang2, Hua Yang2, Tingting Geng3, Ping He1, Jinjian Yao1, Shengyang Yi1, Heping Xu1, Duoyi Wu1, Xiang Wang1, Tianbo Jin4.   

Abstract

CYP2C19 is a highly polymorphic gene and CYP2C19 enzyme results in broad inter-individual variability in response to certain clinical drugs, while little is known about the genetic variation of CYP2C19 in Li Chinese population. The aim of this study was to identify different CYP2C19 mutant alleles and determine their frequencies, along with genotype frequencies, in the Li Chinese population. We used DNA sequencing to investigate promoter, exons, introns, and 3'UTR of the CYP2C19 gene in 100 unrelated healthy Li individuals from Hainan Province, China. We also used SIFT and PolyPhen-2 to predict the protein function of the non-synonymous mutation in CYP2C19 coding regions. We identified 22 different CYP2C19 polymorphisms in the Li Chinese population, including three novel variants (-254A > G, 17807T > C and 58025C > T). The allele frequencies of CYP2C19*1A, *1B, *2A and *3A were 50%, 24%, 24.5%, and 1.5%, respectively. The most common genotype combinations were *1A/*1B (48%) and *1A/*2A (49%). Additionally, the mutation Ala161Pro was predicted to be intolerant and possibly damaging by SIFT and PolyPhen-2, respectively. Our results shed new light on CYP2C19 polymorphisms in Li individuals, which may help to optimize pharmacotherapy effectiveness by providing personalized medicine to this ethnic group.

Entities:  

Keywords:  CYP2C19; Genetic polymorphism; Li Chinese population; ethnic groups

Mesh:

Substances:

Year:  2015        PMID: 26722519      PMCID: PMC4680464     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  31 in total

1.  Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations.

Authors:  S Yamada; M Onda; S Kato; N Matsuda; T Matsuhisa; N Yamada; M Miki; N Matsukura
Journal:  J Gastroenterol       Date:  2001-10       Impact factor: 7.527

2.  Accounting for human polymorphisms predicted to affect protein function.

Authors:  Pauline C Ng; Steven Henikoff
Journal:  Genome Res       Date:  2002-03       Impact factor: 9.043

3.  Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population.

Authors:  Li-Ming Hu; Da-Peng Dai; Guo-Xin Hu; Jie-Fu Yang; Ren-Ai Xu; Li-Ping Yang; Jian-Chang Qian; Ren-Shan Ge; Jian-Ping Cai
Journal:  Pharmacogenomics       Date:  2012-11       Impact factor: 2.533

4.  Induction of CYP2C genes in human hepatocytes in primary culture.

Authors:  S Gerbal-Chaloin; J M Pascussi; L Pichard-Garcia; M Daujat; F Waechter; J M Fabre; N Carrère; P Maurel
Journal:  Drug Metab Dispos       Date:  2001-03       Impact factor: 3.922

5.  CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.

Authors:  Nan He; Feng-Xiang Yan; Song-Lin Huang; Wei Wang; Zhou-Sheng Xiao; Zhao-Qian Liu; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2002-02-22       Impact factor: 2.953

Review 6.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.

Authors:  Elena A Gaikovitch; Ingolf Cascorbi; Przemyslaw M Mrozikiewicz; Jürgen Brockmöller; Roland Frötschl; Karla Köpke; Thomas Gerloff; Jury N Chernov; Ivar Roots
Journal:  Eur J Clin Pharmacol       Date:  2003-07-15       Impact factor: 2.953

Review 9.  Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.

Authors:  David R Nelson; Darryl C Zeldin; Susan M G Hoffman; Lois J Maltais; Hester M Wain; Daniel W Nebert
Journal:  Pharmacogenetics       Date:  2004-01

10.  Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.

Authors:  Tomoko Ota; Yuka Kamada; Mariko Hayashida; Kyoko Iwao-Koizumi; Shigenori Murata; Kenji Kinoshita
Journal:  Int J Med Sci       Date:  2015-01-01       Impact factor: 3.738

View more
  7 in total

1.  CYP2C19 Genotype-Guided Antiplatelet Therapy Among Asian Patients with Ischaemic Stroke.

Authors:  Chia Siang Kow; Abdullah Faiz Zaihan; Syed Shahzad Hasan
Journal:  Clin Drug Investig       Date:  2020-11-25       Impact factor: 2.859

2.  Analysis of CYP2C19 Genetic Polymorphism in a Large Ethnic Hakka Population in Southern China.

Authors:  Zhixiong Zhong; Jingyuan Hou; Bing Li; Qifeng Zhang; Sudong Liu; Cunren Li; Zhidong Liu; Min Yang; Wei Zhong; Pingsen Zhao
Journal:  Med Sci Monit       Date:  2017-12-30

3.  Polymorphisms of drug-metabolizing enzyme CYP2E1 in Chinese Uygur population.

Authors:  Linhao Zhu; Yongjun He; Fanglin Niu; Mengdan Yan; Jing Li; Dongya Yuan; Tianbo Jin
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

4.  Genetic analysis of pharmacogenomic VIP variants in the Blang population from Yunnan Province of China.

Authors:  Chan Zhang; Weiwei Guo; Yujing Cheng; Qi Li; Xin Yang; Run Dai; Linhao Zhu; Wanlu Chen
Journal:  Mol Genet Genomic Med       Date:  2019-04-05       Impact factor: 2.183

5.  CYP2C19 Allele Frequencies in Over 2.2 Million Direct-to-Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System.

Authors:  Yelena Ionova; James Ashenhurst; Jianan Zhan; Hoang Nhan; Cindy Kosinski; Bani Tamraz; Alison Chubb
Journal:  Clin Transl Sci       Date:  2020-07-21       Impact factor: 4.689

6.  Genetic polymorphism analysis of cytochrome P4502E1 (CYP2E1) in a Chinese Tibetan population.

Authors:  Li Wang; Guoxia Ren; Jingjie Li; Linhao Zhu; Fanglin Niu; Mengdan Yan; Jing Li; Dongya Yuan; Tianbo Jin
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

7.  Effects of CYP3A4 Polymorphisms on Drug Addiction Risk Among the Chinese Han Population.

Authors:  Li Wang; Mei Bai; Tianbo Jin; Jianwen Zheng; Yuhe Wang; Yongjun He; Dongya Yuan; Xue He
Journal:  Front Public Health       Date:  2019-11-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.